Molecular structure of Naproxen
Find information on thousands of medical conditions and prescription drugs.

Aleve

Naproxen (trade names: Aleve, Anaprox, Naprogesic, Naprosyn, Naprelan) is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of mild to moderate pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, injury, menstrual cramps, tendinitis, bursitis, and the treatment of primary dysmenorrhea. It works by reducing hormones that cause inflammation and pain in the body. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Although naproxen typically requires a higher dosage than other NSAIDs — a minimal dose is about 200 mg — it binds very well to albumin and thus achieves a longer half-life in the blood than other drugs, lasting up to 12 hours per dose.

Naproxen is also available as a sodium salt, naproxen sodium, which is more rapidly absorbed from the gastrointestinal tract.

Naproxen was first sold as the prescription drug Naprosyn in 1976; naproxen sodium was first sold under the trade name Anaprox in 1980. The Food and Drug Administration (FDA) approved naproxen sodium's use as an over-the-counter drug in 1991 , and it is sold in the United States as Aleve. Naproxen is still a prescription drug in much of the world, including Canada.

Structure and details

Naproxen is a member of the arylacetic acid family of NSAIDs. It is an odorless, white to off-white crystalline substance with a molecular weight of 230.2628. It is lipid-soluble, practically insoluble in water with a low pH (below pH 4), while freely soluble in water at 6 pH and above. Naproxen has a melting point of 153 °C.

Side effects and warnings

Like other NSAIDs, naproxen is capable of producing disturbances in the gastrointestinal tract. Taking the medication with food may help to alleviate this most commonly reported side-effect.

Also like other NSAIDs, naproxen can inhibit the excretion of sodium and lithium. Extreme care must be taken by those who use this drug along with lithium supplements.

Naproxen is also not recommended for use with NSAIDs of the salicylate family (drugs may reduce each other's effects), nor with anticoagulants (may increase risk of bleeding).

In December 2004, the FDA issued a press release following the decision by the National Institutes of Health to halt a five-year study, called the Alzheimer's Disease Anti-Inflammatory Prevention Trial. That study aimed to test both Aleve and Celebrex as preventatives for Alzheimer's disease. Preliminary information from the study showed naproxen elevated the risk of heart attack and stroke by 50%. The FDA advised patients taking over-the-counter naproxen products to:

  • carefully follow the instructions on the label,
  • avoid exceeding the recommended doses for naproxen (220 milligrams twice daily), and
  • take naproxen for no longer than ten days unless a physician directs otherwise.

Read more at Wikipedia.org


[List your site here Free!]


Road to Recovery - Bayer Consumer Care's marketing strategy for Aleve pain medication
From American Demographics, 3/1/01 by Sara Eckel

Byline: SARA ECKEL

BAYER CONSUMER CARE PRESCRIBES SOME STRONG MEDICINE FOR AN AILING BRAND. THE MEMO The problem was big enough to give any marketing manager a headache: How to help a brand that even venerable consumer products giant Procter & Gamble couldn't build. That was the dilemma brand managers from Bayer Consumer Care faced in 1996, when they inherited Aleve, the over-the-counter pain medication, from P&G. With P&G, Aleve had floundered since its 1994 launch, never gaining more than a 6 percent share of the market. How could Bayer strengthen Aleve's anemic sales?

THE DISCOVERY First, Bayer set out to identify the Aleve user. In 1997, the Bayer team hired New York-based CLT Research Associates to conduct 800 in-home interviews, a random sample of men and women aged 18 to 75 who had used a nonprescription pain reliever in the past year. CLT discovered that about 24 percent of those interviewed fell into a segment called "pain busters" - consumers who were heavy users of over-the-counter painkillers, and who were eager to try new brands. About 35 percent of these pain busters had tried Aleve in the past year, but their medicine cabinet was full of other brands as well. The challenge: How to convince these pain busters to choose Aleve above other options?

To conjure up an appropriate marketing message, Bayer tapped Moskowitz Jacobs Inc. The White Plains, New York-based market research firm asked 249 respondents aged 18 to 69 to rate various statements about Aleve. The company discovered that statements that promised "control over pain," or "freedom to do the things you want," were important emotional triggers for pain buster consumers. Moskowitz also learned that consumers were interested in minimizing the number of pills they took to relieve pain. Aleve's claim of all-day pain relief with just two blue pills - compared with as many as eight pills of competing brands - would warrant sober attention from consumers.

The next step: to marry the imagery of freedom and control with Aleve's demographic and psychographic target market. Bayer managers analyzed data from Medioscope - a syndicated source for OTC drug data - Nielsen Panel Data, MRI, and Simmons and fleshed out the findings with a series of focus groups moderated by Croton-on-Hudson, New York-based Viewpoints Consulting, Inc. The analysis revealed that Aleve's users were more likely to suffer from arthritis and back pain than the average analgesic user. The team also discovered that loyal Aleve users juggle many commitments in their lives, and are passionate about their accomplishments. This helped Bayer to "put a face" on the benefit of taking Aleve: "liberation from tough pain, making a dramatic difference in the quality of your life."

THE TACTICS Aleve's "Dramatic Difference" ad campaign launched in 1999, with spots designed by BBDO Chicago. The new campaign mirrored the message that Aleve users had stressed in the focus groups. Each ad was framed as a letter from an Aleve user, who writes to thank the brand for getting rid of her pain and helping her return to her life. The most successful spot, "Donna W," portrays an older woman who was having trouble walking and had spent years diligently searching for a way to end her pain - until finally she found a doctor who suggested Aleve. By the end of the commercial, she's dancing. In the final frame, she's concluding the letter and thanking the brand for improving her life.

THE PAYOFF Thanks to BBDO's Dramatic Difference ad campaign, Aleve sales have started to live up to its potential. In 2000, sales of the medication were 16 percent higher than in 1999. In a flat category, Aleve's market share climbed to 7 percent, its all-time best. The number of consumers who could recall the brand unaided increased by 8 percentage points between 1999 and 2000 - to 44 percent in 2000. Similarly, unaided recall of Aleve advertisements went up 7 percentage points, to 33 percent in 2000. Empowering women to rid themselves of pain seems to have been just the medicine that Aleve needed.

Advertiser Bayer Product Aleve Campaign "Dramatic Difference" Advertising Agency BBDO Chicago Research Companies IRI, Monroe Mendelsohn Research, CLT Research Associates Inc., Viewpoints Consulting, Carol Bernstein Associates, Ipsos-ASI, Media Marketing Assessment, Medioscope, Nielsen Panel Data, Simmons Market Research Bureau

COPYRIGHT 2001 Copyright by Media Central Inc., A PRIMEDIA Company. All rights reserved.
COPYRIGHT 2003 Gale Group

Return to Aleve
Home Contact Resources Exchange Links ebay